BRPI0509209A - compound, methods for contraception, hormone replacement therapy, treatment or prevention of hormone dependent neoplastic disease; treatment of dysfunctional bleeding or polycystic ovarian syndrome; estrus synchronization; acne treatment or hirsutism treatment, and for compound preparation, pharmaceutical composition, pharmaceutical kit, and use of a compound - Google Patents

compound, methods for contraception, hormone replacement therapy, treatment or prevention of hormone dependent neoplastic disease; treatment of dysfunctional bleeding or polycystic ovarian syndrome; estrus synchronization; acne treatment or hirsutism treatment, and for compound preparation, pharmaceutical composition, pharmaceutical kit, and use of a compound

Info

Publication number
BRPI0509209A
BRPI0509209A BRPI0509209-4A BRPI0509209A BRPI0509209A BR PI0509209 A BRPI0509209 A BR PI0509209A BR PI0509209 A BRPI0509209 A BR PI0509209A BR PI0509209 A BRPI0509209 A BR PI0509209A
Authority
BR
Brazil
Prior art keywords
treatment
compound
contraception
hormone
prevention
Prior art date
Application number
BRPI0509209-4A
Other languages
Portuguese (pt)
Inventor
Bogdan Kazimierz Wilk
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0509209A publication Critical patent/BRPI0509209A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ink Jet (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.
BRPI0509209-4A 2004-04-08 2005-04-07 compound, methods for contraception, hormone replacement therapy, treatment or prevention of hormone dependent neoplastic disease; treatment of dysfunctional bleeding or polycystic ovarian syndrome; estrus synchronization; acne treatment or hirsutism treatment, and for compound preparation, pharmaceutical composition, pharmaceutical kit, and use of a compound BRPI0509209A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56056904P 2004-04-08 2004-04-08
PCT/US2005/011757 WO2005100346A1 (en) 2004-04-08 2005-04-07 Thioamide derivatives as progesterone receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0509209A true BRPI0509209A (en) 2007-08-28

Family

ID=34965700

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509209-4A BRPI0509209A (en) 2004-04-08 2005-04-07 compound, methods for contraception, hormone replacement therapy, treatment or prevention of hormone dependent neoplastic disease; treatment of dysfunctional bleeding or polycystic ovarian syndrome; estrus synchronization; acne treatment or hirsutism treatment, and for compound preparation, pharmaceutical composition, pharmaceutical kit, and use of a compound

Country Status (14)

Country Link
US (4) US7358246B2 (en)
EP (1) EP1732921B1 (en)
JP (1) JP4869221B2 (en)
CN (1) CN100522960C (en)
AT (1) ATE413398T1 (en)
AU (1) AU2005233591B2 (en)
BR (1) BRPI0509209A (en)
CA (1) CA2561014C (en)
DE (1) DE602005010840D1 (en)
DK (1) DK1732921T3 (en)
ES (1) ES2317223T3 (en)
MX (1) MXPA06011696A (en)
PL (1) PL1732921T3 (en)
WO (1) WO2005100346A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4950027B2 (en) * 2004-04-08 2012-06-13 ワイス・エルエルシー Method for minimizing thioamide impurities
JP4869221B2 (en) * 2004-04-08 2012-02-08 ワイス・エルエルシー Thiamide derivatives as progesterone receptor modulators
GT200500185A (en) * 2004-08-09 2006-04-10 PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND THEIR USES
US20070093548A1 (en) * 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
WO2008021338A2 (en) * 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
JP2011507853A (en) * 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド Dosage regimens and pharmaceutical compositions and packages for emergency contraception
CN107281215A (en) * 2016-04-01 2017-10-24 复旦大学附属妇产科医院 Purposes of the hydrogen sulfide donor sodium hydrosulfide in pharmacy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4295987A (en) * 1979-12-26 1981-10-20 The Procter & Gamble Company Cross-linked sodium polyacrylate absorbent
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5459151A (en) * 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5854388A (en) * 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5756127A (en) * 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
FI971385A0 (en) 1997-04-04 1997-04-04 Bioxid Oy Biocompatible composition, methodological method
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
ES2301482T3 (en) * 1999-05-04 2008-07-01 Wyeth CYCLLOTIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS.
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
EA005034B1 (en) * 1999-05-04 2004-10-28 Америкэн Хоум Продактс Корпорейшн Thio-oxindole derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
CN1368952A (en) * 1999-08-10 2002-09-11 史密丝克莱恩比彻姆公司 1,4-substituted 4,4-diaryl cyclohexanes
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP4716547B2 (en) * 2000-08-10 2011-07-06 住友精化株式会社 Method for producing 2-phenylthiazoles
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
EP1514552A4 (en) * 2002-06-06 2008-04-02 Eisai R&D Man Co Ltd Novel fused imidazole derivative
BR0312092A (en) * 2002-06-25 2005-03-22 Wyeth Corp Use of thiooxyindole derivatives in the treatment of skin disorders
EP1515725A4 (en) 2002-06-25 2005-09-21 Wyeth Corp Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
MXPA04012420A (en) * 2002-06-25 2005-04-19 Wyeth Corp Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders.
IL165395A0 (en) * 2002-06-25 2006-01-15 Wyeth Corp Use of thio-oxubdile derivatives in treatment of hormone-related conditions
CN1946665B (en) 2004-04-08 2011-06-15 惠氏公司 Method for preparing 3-cyclopentyloxy-4-methoxybenzaldehyde
JP4869221B2 (en) * 2004-04-08 2012-02-08 ワイス・エルエルシー Thiamide derivatives as progesterone receptor modulators
JP4950027B2 (en) 2004-04-08 2012-06-13 ワイス・エルエルシー Method for minimizing thioamide impurities
CN1953967B (en) 2004-04-27 2013-03-13 惠氏公司 Purification of progesterone receptor modulators

Also Published As

Publication number Publication date
US7358246B2 (en) 2008-04-15
US20090143345A1 (en) 2009-06-04
JP4869221B2 (en) 2012-02-08
US20050227971A1 (en) 2005-10-13
US8168672B2 (en) 2012-05-01
DE602005010840D1 (en) 2008-12-18
EP1732921B1 (en) 2008-11-05
AU2005233591B2 (en) 2011-10-27
PL1732921T3 (en) 2009-04-30
US20100197645A1 (en) 2010-08-05
EP1732921A1 (en) 2006-12-20
ES2317223T3 (en) 2009-04-16
WO2005100346A1 (en) 2005-10-27
US7511071B2 (en) 2009-03-31
JP2007532564A (en) 2007-11-15
US7659265B2 (en) 2010-02-09
CA2561014C (en) 2013-09-10
MXPA06011696A (en) 2006-12-14
AU2005233591A1 (en) 2005-10-27
US20080167299A1 (en) 2008-07-10
CN1938299A (en) 2007-03-28
ATE413398T1 (en) 2008-11-15
CA2561014A1 (en) 2005-10-27
DK1732921T3 (en) 2009-02-23
CN100522960C (en) 2009-08-05

Similar Documents

Publication Publication Date Title
BRPI0509209A (en) compound, methods for contraception, hormone replacement therapy, treatment or prevention of hormone dependent neoplastic disease; treatment of dysfunctional bleeding or polycystic ovarian syndrome; estrus synchronization; acne treatment or hirsutism treatment, and for compound preparation, pharmaceutical composition, pharmaceutical kit, and use of a compound
NO20022292L (en) New topical estrogen progestogen preparations with systemic effect
DE602005026290D1 (en) COMPOSITIONS OF DELAYED RELEASE WITH PROGESTERONE RECEPTOR MODULATORS
AR057060A1 (en) TANAPROGET COMPOSITIONS CONTAINING ETHYL ESTRADIOL
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
EA200900451A1 (en) METHOD OF OBTAINING COMPOSITION OF ESTRADIOL WITH SLOW-BREAKDOWN (OPTIONS), ESTRADIOL AND CHOLESTEROL MICROSPHERE AND METHOD FOR SIMULTANEOUS CONTRACEPTION AND HORSE SUBSTITUTION
BRPI0416700A (en) methods for treating obesity, achieving desirable weight loss, avoiding undesirable weight gain, and facilitating weight loss in a non-depressed individual, methods of maintaining a stable weight and reducing body weight in an individual pharmaceutical composition and kit
CL2009001936A1 (en) Pyridazine derived compounds, 11beta-hsd1 inhibitors; pharmaceutical composition; preparation procedure; and use in the treatment of diabetes, obesity, dyslipidemia, eating disorders and hypertension (divisional application 1720-2006).
BRPI0819703A2 (en) Use of protein tyrosine phosphatase and human growth hormone inhibitors, use of igf1 and a protein tyrosine phosphatase inhibitor and pharmaceutical combination composition for the treatment of muscle atrophy and related disorders
BG66075B1 (en) Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
IL176738A0 (en) Selective estrogen receptor modulators for the treatment of vasomotor symptoms
WO2008049516A3 (en) Transdermal therapeutic system comprising norelgestromin for contraception and hormone replacement
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
SG152257A1 (en) Topical preparation containing ambroxol
CR7611A (en) USE OF CILOTIOCARBAMATE DERIVATIVES IN TREATMENT OF CONDITIONS RELATED TO HORMONE
AR033042A1 (en) HORMONAL REPLACEMENT THERAPY
AR044350A1 (en) MICROENCAPSULATED ANALGESIC HOSE AND TOPICO PATCH FOR PAIN TREATMENT
BRPI0507987A (en) glucocorticoid receptor modulating methods and compounds
EA200702604A1 (en) Derivatives of benzofuranone as a non-steroidal modulator of the progesterone receptor
PA8633801A1 (en) DERIVATIVES OF SULFAMOYLBENZOATE AND SULFAMOYLAMINOBENZOATE OF ESTRIOL, AND DERIVATIVES OF SULFAMOYLBENZOATE AND SULFAMOYLAMINOBENZOATE OF STETROL
BRPI0409588A (en) compound, pharmaceutical composition, methods for selectively binding to the estrogen receptor beta in a patient, treating a patient afflicted with a beta estrogen receptor mediated disease condition, treating prostate cancer and benign prostatic hyperplasia in a patient, and , use of a compound
EE200300310A (en) Pharmaceutical composition containing estrogen and other hormones in combination with ascorbate, lysine, proline and other active substances, and its use
EA200970376A1 (en) PEG-ILI PARATYROID HORMONE AS A MODULATOR OF A PARATYROID HORMONE RECEPTOR AND ITS APPLICATION
HUP0202460A2 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: WYETH LLC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.